Tags

Type your tag names separated by a space and hit enter

Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised.
J Clin Microbiol. 2006 Jul; 44(7):2512-7.JC

Abstract

We evaluated three CDC-suggested approaches for confirming positive nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: (i) repeat the original test on the original specimen, (ii) retest the original specimen with a different test, and (iii) perform a different test on a duplicate specimen. For approach 1, specimens (genital swabs or first-catch urine [FCU]) initially positive by the Abbott LCx Probe System Chlamydia trachomatis Assay (LCx; Abbott Laboratories), the APTIMA Combo 2 Assay (AC2; Gen-Probe Inc.), the Amplicor CT/NG Assay (PCR; Roche Diagnostics Corp.), or the BD ProbeTec ET System C. trachomatis amplified-DNA assay (SDA; Becton Dickinson Diagnostic Systems) were retested by the same NAAT. In several evaluations, multiple efforts were made to confirm the original positive result. For approach 2, specimens initially positive by SDA and the Hybrid Capture 2 CT-ID DNA Test (HC2; Digene Corp.) were retested by different NAATs (SDA, PCR, AC2, and the APTIMA assay for C. trachomatis [ACT]). For approach 3, duplicate male urethral or cervical swabs were tested by SDA or by both AC2 and ACT. FCU specimens were tested by all three tests. We found that 84 to 98% of SDA, LCx, PCR, and AC2 positive results were confirmed by a repeat test and that 89 to 99% of SDA and AC2 and 93% of HC2 positive results were confirmed by different NAATs, but that some NAATs cannot be used to confirm other NAATs. The use of repeat testing did not confirm 11% of C. trachomatis SDA positive results that could be confirmed by more extensive testing. Doing more testing confirms more positive results; >90% of all positive NAATs could be confirmed.

Authors+Show Affiliations

Chlamydia Research Laboratory, Department of Laboratory Medicine, University of California, San Francisco, 1001 Potrero Avenue, Bldg. 30 Room 416, San Francisco, CA 94110, USA. Julius.Schachter@ucsf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16825373

Citation

Schachter, Julius, et al. "Detection of Chlamydia Trachomatis By Nucleic Acid Amplification Testing: Our Evaluation Suggests That CDC-recommended Approaches for Confirmatory Testing Are Ill-advised." Journal of Clinical Microbiology, vol. 44, no. 7, 2006, pp. 2512-7.
Schachter J, Chow JM, Howard H, et al. Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. J Clin Microbiol. 2006;44(7):2512-7.
Schachter, J., Chow, J. M., Howard, H., Bolan, G., & Moncada, J. (2006). Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. Journal of Clinical Microbiology, 44(7), 2512-7.
Schachter J, et al. Detection of Chlamydia Trachomatis By Nucleic Acid Amplification Testing: Our Evaluation Suggests That CDC-recommended Approaches for Confirmatory Testing Are Ill-advised. J Clin Microbiol. 2006;44(7):2512-7. PubMed PMID: 16825373.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. AU - Schachter,Julius, AU - Chow,Joan M, AU - Howard,Holly, AU - Bolan,Gail, AU - Moncada,Jeanne, PY - 2006/7/11/pubmed PY - 2006/10/25/medline PY - 2006/7/11/entrez SP - 2512 EP - 7 JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 44 IS - 7 N2 - We evaluated three CDC-suggested approaches for confirming positive nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: (i) repeat the original test on the original specimen, (ii) retest the original specimen with a different test, and (iii) perform a different test on a duplicate specimen. For approach 1, specimens (genital swabs or first-catch urine [FCU]) initially positive by the Abbott LCx Probe System Chlamydia trachomatis Assay (LCx; Abbott Laboratories), the APTIMA Combo 2 Assay (AC2; Gen-Probe Inc.), the Amplicor CT/NG Assay (PCR; Roche Diagnostics Corp.), or the BD ProbeTec ET System C. trachomatis amplified-DNA assay (SDA; Becton Dickinson Diagnostic Systems) were retested by the same NAAT. In several evaluations, multiple efforts were made to confirm the original positive result. For approach 2, specimens initially positive by SDA and the Hybrid Capture 2 CT-ID DNA Test (HC2; Digene Corp.) were retested by different NAATs (SDA, PCR, AC2, and the APTIMA assay for C. trachomatis [ACT]). For approach 3, duplicate male urethral or cervical swabs were tested by SDA or by both AC2 and ACT. FCU specimens were tested by all three tests. We found that 84 to 98% of SDA, LCx, PCR, and AC2 positive results were confirmed by a repeat test and that 89 to 99% of SDA and AC2 and 93% of HC2 positive results were confirmed by different NAATs, but that some NAATs cannot be used to confirm other NAATs. The use of repeat testing did not confirm 11% of C. trachomatis SDA positive results that could be confirmed by more extensive testing. Doing more testing confirms more positive results; >90% of all positive NAATs could be confirmed. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/16825373/Detection_of_Chlamydia_trachomatis_by_nucleic_acid_amplification_testing:_our_evaluation_suggests_that_CDC_recommended_approaches_for_confirmatory_testing_are_ill_advised_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=16825373 DB - PRIME DP - Unbound Medicine ER -